ImmunoGenes Competitors and Similar CompaniesClear all

ImmunoGenes's competitors and similar companies include TES Pharma, Akouos, Novartis and Pfizer.

	ImmunoGenes ImmunoGenes is a company that specializes in custom antibody services and transgenic animal model development.	TES Pharma TES Pharma is a research-based biopharmaceutical company focused on delivering preclinical candidates.	Akouos Akouos is a precision genetic medicine company focused on developing gene therapies to treat hearing disorders.	Novartis Novartis is a company that researches, develops, manufactures, and markets healthcare products.	Pfizer Pfizer is a research-based biopharmaceutical company engaged in the discovery, development, manufacture, and distribution of healthcare products.
Founding Date	Founding Date 2007	Founding Date 2011	Founding Date 2016	Founding Date 1996	Founding Date 1849
Type	Type Private	Type Private	Type Subsidiary	Type Public	Type Public
Tags	Tags Healthcare biotech clinical research drug development genetics pharma	Tags Healthcare biotech clinical research drug development genetics pharma	Tags Healthcare biotech clinical research drug development genetics pharma	Tags Healthcare biotech clinical research drug development oncology pharma	Tags Healthcare biotech clinical research drug development pharma
Locations	Locations HQ	Locations Taverne di Corciano, IT HQ Perugia, IT	Locations Boston, US HQ	Locations Basel, CH HQ Tirana, AL Buenos Aires, AR Macquarie Park, AU Kundl, AT Unterlangkampfen, AT Wien, AT see more	Locations New York, US HQ Buenos Aires, AR Villa Adelina, AR Footscray, AU Mulgrave, AU Sydney, AU Wien, AT see more
Employees	Employees 2	Employees N/A	Employees 913% decrease	Employees 75,883	Employees 81,0008% decrease
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) $56.7b (FY, 2025)	Revenue (est.) $62.6b (FY, 2025)
Cost of goods	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A	Cost of goods $8.4b (FY, 2025)	Cost of goods $16.1b (FY, 2025)
Gross profit	Gross profit N/A	Gross profit N/A	Gross profit N/A	Gross profit $49.8b (FY, 2025)	Gross profit $46.5b (FY, 2025)
Net income	Net income N/A	Net income N/A	Net income ($86.7m) (FY, 2021)	Net income $14b (FY, 2025)	Net income $7.8b (FY, 2025)
Operating ⚠
Phase III Trials Products	Phase III Trials Products N/A	Phase III Trials Products N/A	Phase III Trials Products N/A	Phase III Trials Products 44 (FY, 2022)	Phase III Trials Products 32 (FY, 2024)
Registration Phase Products	Registration Phase Products N/A	Registration Phase Products N/A	Registration Phase Products N/A	Registration Phase Products 8 (FY, 2022)	Registration Phase Products 5 (FY, 2024)
Funding
Total funding raised	Total funding raised N/A	Total funding raised N/A	Total funding raised $ 162.5m	Total funding raised $ 6.5m	Total funding raised N/A